Optinose

Discussion in 'Biotech Startups' started by anonymous, Sep 27, 2017 at 11:08 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

     

  2. anonymous

    anonymous Guest

    “Some chick...”, I think you mean Kelly Bisson.
     
  3. anonymous

    anonymous Guest

    Great news you have a second product to try to sell!
    Complete failure by Peter on all levels.

    Optinose (NASDAQ: OPTN) today announced the Company received written notice from Avanir Pharmaceuticals, Inc. of its election to terminate the License Agreement to develop and commercialize ONZETRA® XSAIL® in the United States, Canada, and Mexico. As a result, the License Agreement is expected to terminate on March 10, 2019.

    Upon termination of the license agreement, Optinose may elect to continue to commercialize ONZETRA XSAIL itself or through a new licensee.

    “Optinose intends to evaluate its options with respect to the future of ONZETRA XSAIL,” stated CEO Peter Miller. “What is important is that we believe the termination of the license agreement will not have a material effect on the Company’s use of cash. Our strategic focus is on building a leading company to serve the unmet needs of ENT and Allergy Specialists and their patients. As a result, we intend to focus on options for ONZETRA XSAIL that involve minimal organizational burden for Optinose, which may include identifying and licensing ONZETRA XSAIL to a new partner.”

    Through September 30, 2018, under the terms of the License Agreement with Avanir, Optinose has received aggregate cash payments of $70 million in connection with the initial signing and subsequent payments.
     
  4. anonymous

    anonymous Guest

    the death of the licensing ONZETRA® XSAIL® agreement with Avanir is a big deal. We were counting on them to take the burden of development-both $$ and time off our plates- so we could focus on our in line product. This says two things:
    1) the product doesn't have a future or
    2) if it does we
    a) have to it ourselves or
    b) find a new partner

    Scenario 1 is a HUGE problem
    Scenario 2 is a cash flow problem.

    Hence the reason for the further stanking today! Nice job Peter and Ramy!
     
  5. anonymous

    anonymous Guest

    Never had the displeasure of meeting Kelly. I am, however, acquainted with several of the current Optinose employees, one quite well. I can only say that Peter's secretary... you know, his barometer of "nice", could not possibly be more wrong in her assessment of the personalities of those folks. In particular, the former J & J failures that are currently staffing Optinose are anything but nice. Let's charitably say that many of them have personality disorders, more than are morally challenged, and at least one is a full blown sociopath. Congratulations, Peter, you have done a fine job of putting this company together.
     
  6. anonymous

    anonymous Guest

    Do you think reps will get laid off? Guess the possibility of rolling over will not happen
     
  7. anonymous

    anonymous Guest

    Same chance as hitting our sales goal this year
     
  8. anonymous

    anonymous Guest

    Stock below 7. Major investors are unloading their positions slowly to avoid a short squeeze.
     
  9. anonymous

    anonymous Guest

    such a surprise..smh..hate to say it, but didn’t we all know where this was headed months ago?!!
     
  10. anonymous

    anonymous Guest

    headed under 6 soon...you really thought you could snow them, huh Peter??!
     
  11. anonymous

    anonymous Guest

    we are below $6.00 now. Happy New Year!!
     
  12. anonymous

    anonymous Guest

    Blue Whale loves shorting Optinose (sell quietly on the way down)
     
  13. anonymous

    anonymous Guest

    optinose never not an awful name. Suggestions?
     
  14. anonymous

    anonymous Guest

    Has Tom's replacement been named?
     
  15. anonymous

    anonymous Guest

    Peter has another yes-man lined up and ready to kick some ass.
     
  16. anonymous

    anonymous Guest

    2 RBD openings. What's going on? I would guess that the NE is dead last in the company with little to no coverage or advantages from a coverage standpoint, but why Texas?
     
  17. anonymous

    anonymous Guest

    Even in TX the product is so weak they dont cover it
     
  18. anonymous

    anonymous Guest


    I heard Houston was its best market - True or False?
     
  19. anonymous

    anonymous Guest

    where did tom gibbs go, he is a great guy
     
  20. anonymous

    anonymous Guest

    Yes he is real goddamn genius that guy